Medtronic Receives the US FDA’s Approval for its Percept PC Neurostimulator with BrainSense Technology

 Medtronic Receives the US FDA’s Approval for its Percept PC Neurostimulator with BrainSense Technology

Medtronic Receives the US FDA’s Approval for its Percept PC Neurostimulator with BrainSense Technology

Shots:

  • Percept is the first and only DBS neurostimulation system with BrainSens technology, allowing it to capture brain signals while delivering therapy to patients with neurologic disorders associated with Parkinson’s disease, essential tremor, dystonia, epilepsy, and OCD
  • Percept PC DBS system features 3T and 1.5T full-body MRI scans, smart battery and low pulse width and has received CE mark in Jan’2020
  • Mayo Clinic will be the first to implant the Medtronic’s DBS system in the US. DBS is an individualized therapy delivered from a small pacemaker-like device, placed under the skin of the chest or abdomen, to send electrical signals through leads to a targeted area in the brain related to the symptoms of a neurological disorder

Click here to read full press release/ article | Ref: Medtronic | Image: Medtronic

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post